A multi-center study found that AI-assisted prostate biopsy review improved diagnostic consistency, reduced lab workloads, and cut turnaround times by nearly a day in UK NHS pathology labs.
Cleveland Diagnostics has received ISO 13485:2016 certification for its IsoPSA Assay, supporting scaled U.S. commercialization following recent FDA approval for prostate cancer risk assessment.
The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More
A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.
Read More
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More
The AR-ctDETECT test identifies circulating tumor DNA in advanced prostate cancer patients, providing critical insights for prognostication.
Read More
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read More
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
Read More
A new prostate cancer screening method could help better predict which patients need to undergo a biopsy, reducing unnecessary procedures.
Read More
GRAIL’s Galleri multi-cancer early detection test demonstrates strong performance in preferentially identifying aggressive prostate cancers.
Read More
A newly discovered class of RNA molecules in extracellular vesicles could serve as biomarkers for non-invasive cancer diagnosis.
Read More
A retrospective study shows that combining risk markers, MRI evaluation, and AI can more accurately predict prostate cancer risk.
Read More